Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07446257 · ClinicalTrials.gov registry record · Early Phase 1
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
NCT07446257 is a Early Phase 1 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT07446257, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Interventions
- DRUG Cadonilimab
- DRUG ateganosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-29 |
| Est. Completion | 2030-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07446257
The ClinicalTrials.gov registry entry for NCT07446257 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cadonilimab is the first listed.
NCT07446257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07446257 about?
NCT07446257 is a clinical study titled "THIO and Cadonilimab in Resectable Hepatocellular Carcinoma". The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
What is the current status of trial NCT07446257?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2026-06-29. Estimated completion is 2030-09-01.
What interventions are being tested in trial NCT07446257?
The interventions under investigation include: Cadonilimab (DRUG), ateganosine (DRUG).
Who is sponsoring clinical trial NCT07446257?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.